TDO-IN-1

SKU: orb1688836

Description

TDO-IN-1 is a potent, selective, and orally bioavailable inhibitor of tryptophan 2,3-dioxygenase (TDO) that also inhibits IDO. It demonstrates antitumor activity in research models by reversing tumor-mediated immune suppression, making it a tool for studying cancer immunology in both in vitro and in vivo settings.

Research Area

Metabolism Research

Key Properties

• CAS Number: 2490672-92-7
• MW: 350.3
• Purity: 99.86% (May vary between batches)
• Formula: C₁₆H₁₃F₃N₄O₂
• SMILES: N(CC1=C(N(=O)=O)C=C(C)C=C1)C2=C3C(=CC(C(F)(F)F)=C2)NN=C3
• Target: Others,IDO,Indoleamine 2,3-Dioxygenase (IDO)
• Solubility: DMSO:60 mg/mL (171.28 mM)

Bioactivity

• Target IC50:
  MOLM-13:3.43 μM|Jurkat cells:7.25 μM|Hepa1-6:5.08 μM|B16 cells:37.39 μM|HepG2 cells:0.54 μM|TDO:0.62 μM|H22 cells:1.34 μM
• In Vivo:
  Administered orally at a dose of 25 mg/kg once daily for 9 days, TDO-IN-1 (HT-28) enhances the efficacy of tumor immunotherapy in CT26 tumors expressing TDO. This treatment substantially inhibits the proliferation of CT26 tumors in mice.
  Read more...
• In Vitro:
  TDO-IN-1 (HT-28) exhibits significant tumoricidal effects on various tumor lines at concentrations ranging from 0 to 100 μM over 24 hours, with IC50 values of 0.54 μM (HepG2), 5.08 μM (Hepa1-6), 1.34 μM (H22), 37.39 μM (B16), 3.43 μM (MOLM-13), and 7.25 μM (Jurkat). Additionally, TDO-IN-1 (0-100 μM; 24 h) shows minimal cytotoxicity against normal cells (HEK 293) at concentrations below 10 μM.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

TDO

Compound Identifiers

PubChem CID

165412459